Suppr超能文献

早产儿血浆 RELMβ 和血小板减少症早期诊断坏死性小肠结肠炎:一项初步研究。

Early diagnosis of necrotizing enterocolitis by plasma RELMβ and thrombocytopenia in preterm infants: A pilot study.

机构信息

Department of Neonatology, Bao'an Maternal and Child Health Hospital of Shenzhen, Jinan University, Guangdong, China.

Department of Neonatology, Shenzhen Children's Hospital, Shenzhen, China.

出版信息

Pediatr Neonatol. 2019 Aug;60(4):447-452. doi: 10.1016/j.pedneo.2019.01.006. Epub 2019 Jan 22.

Abstract

BACKGROUND

As the inflammatory regulators, Resistin-like molecule β (RELMβ) and Resistin might be potential biomarkers of necrotizing enterocolitis (NEC), while thrombocytopenia is often related to the severity of NEC, clinical observation suggests that thrombocytopenia might be an early biomarker of NEC. The aim of this study was to evaluate whether RELMβ, Resistin and thrombocytopenia could be biomarkers for early diagnosis of NEC in preterm infants.

METHODS

From January 2016 to March 2018, twenty-nine NEC preterm infants who were diagnosed with NEC (Bell's stage ≥Ⅱ) by two independent neonatologists and twenty-nine non NEC preterm infants at neonatal intensive care unit in our hospital were enrolled in this case-control study. Preterm infants with a history of serious infections (sepsis, pneumonia), asphyxia, and congenital malformations were excluded from the study. The plasma RELMβ and Resistin were evaluated by enzyme linked immunosorbent assay (ELISA) and serum platelet levels were measured directly by ordinary light microscope at the diagnosis of NEC (Bell's stage ≥Ⅱ).

RESULTS

Plasma RELMβ levels in NEC group were significantly higher than control group (P < 0.05). The optimal cut-off value of RELMβ determined by receiver operating characteristic curve (ROC) was 378.3 ng/L. The overall estimates for sensitivity and specificity of high RELMβ concentrations in the detection of neonatal NEC were 71.4% and 91.7%, respectively. No significant difference was found in plasma Resistin levels between two groups (P > 0.05). If platelet level was less than 157 × 10/L, the sensitivity and specificity were 69.34% and 82.87%, respectively. Interestingly, the combination of RELMβ and thrombocytopenia increased sensitivity and specificity to 82.89% and 93.21%, respectively.

CONCLUSION

The combination of RELMβ and thrombocytopenia was a reliable biomarker for the early diagnosis of NEC in this study with 82.89% sensitivity and 93.21% specificity, respectively.

摘要

背景

作为炎症调节剂,抵抗素样分子β(RELMβ)和抵抗素可能是坏死性小肠结肠炎(NEC)的潜在生物标志物,而血小板减少症常与 NEC 的严重程度有关,临床观察表明血小板减少症可能是 NEC 的早期生物标志物。本研究旨在评估 RELMβ、抵抗素和血小板减少症是否可作为早产儿 NEC 的早期诊断标志物。

方法

本病例对照研究纳入了 2016 年 1 月至 2018 年 3 月期间我院新生儿重症监护病房由两位独立新生儿科医生诊断为 NEC(Bell 分期≥Ⅱ)的 29 例 NEC 早产儿和 29 例非 NEC 早产儿。排除有严重感染(败血症、肺炎)、窒息和先天性畸形病史的早产儿。通过酶联免疫吸附试验(ELISA)评估血浆 RELMβ 和抵抗素水平,并在 NEC(Bell 分期≥Ⅱ)诊断时直接用普通光镜测量血清血小板水平。

结果

NEC 组血浆 RELMβ 水平明显高于对照组(P<0.05)。受试者工作特征曲线(ROC)确定的 RELMβ 最佳截断值为 378.3ng/L。高 RELMβ 浓度检测新生儿 NEC 的总体敏感性和特异性估计值分别为 71.4%和 91.7%。两组间血浆抵抗素水平无显著差异(P>0.05)。如果血小板水平低于 157×10/L,则敏感性和特异性分别为 69.34%和 82.87%。有趣的是,RELMβ 和血小板减少症的联合使用可将敏感性和特异性分别提高至 82.89%和 93.21%。

结论

在本研究中,RELMβ 和血小板减少症的联合使用是 NEC 早期诊断的可靠生物标志物,敏感性和特异性分别为 82.89%和 93.21%。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验